Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment

Acta Oncologica

Volumn 37, Issue 4, 1998, Pages 365-368

  Haarstad, Helge ^a   Lønning, Per E ^b   Gundersen, Stein ^c   Wist, Erik ^d   Raabe, Nils ^e   Kvinnsland, Stener ^c  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DROLOXIFENE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONSTIPATION; DOSE RESPONSE; DRUG EFFECT; FATIGUE; FEMALE; HOT FLUSH; HUMAN; METRORRHAGIA; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; VAGINITIS; VERTIGO; WEIGHT GAIN;

EID: 0031880126     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698430584     Document Type: Article

References (15)

1. Jordan VC. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993; 339: 71-85.
2. Goldhirsch A, Gelber RD. Endocrine therapies of breast cancer. Semin Oncol 1996; 23: 494-505.
3. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13: 513-29.
4. Hasmann M, Rattel B, Löser R. Preclinical data for droloxifene. Cancer Lett 1994; 84: 101-16.
5. Haarstad H, Gundersen S, Wist E, Raabe N, Mella O, Kvinnsland S. Droloxifene - a new anti-estrogen. A phase II study in advanced breast cancer. Acta Oncol 1992; 31: 425-8.
6. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13: 89-94.
7. Geisler J, Haarstad H, Gundersen S, Raabe N, Kvinnsland S, Lonning PE. Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. J Endocrinol 1995; 146: 359-63.
8. Grill HJ, Pollow K. Pharmacokinetics of droloxifene and its metabolites in breast cancer patients. Am J Clin Oncol 1991; 14 (Suppl 2): 21-9.
9. Lønning PE. New endocrine drugs for treatment of advanced breast cancer. Acta Oncol 1990; 29: 379-86.
10. Roos WK, Oeze L, Löser R, Eppenberger U. Antiestrogen action of 3-hydroxy-tamoxifen in the human breast cancer cell line MCF-7. J Natl Cancer Inst 1983; 71: 55-9.
11. Eppenberger U, Wosikowski K, Küng W. Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol 1991; 14 (Suppl 2): 5-14.
12. Kvinnsland S. Droloxifene, a new antiestrogen. Hormonal influences in post-menopausal breast cancer patients. Am J Clin Oncol 1991; 14 (Suppl 2): 46-51.
13. Jordan VC. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Ann Rev Pharmacol Toxicol 1995; 35: 195-211.
14. Bruning PF. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer 1992; 28A: 1404-7.
15. Rose C, Mourildsen HT. Endocrine therapy of advanced breast cancer. Acta Oncol 1988; 27: 721-8.